FRANK E.MOTTFRANK E. MOTT12407MOTT, FRANK E.Associate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBiostatisticsHead & Neck SurgeryPalliative Care & Rehabilitation MedicineRadiation OncologyThoracic Head & Neck Medical OncologyMD AndersonJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorFAYE MJOHNSONFAYE M JOHNSON8515JOHNSON, FAYE MAssociate ProfessorERICH MSTURGISERICH M STURGIS8744STURGIS, ERICH MProfessorEDUARDOBRUERAEDUARDO BRUERA8804BRUERA, EDUARDOProfessorRENATAFERRAROTTORENATA FERRAROTTO9635FERRAROTTO, RENATAAssistant ProfessorDAVIDHUIDAVID HUI9525HUI, DAVIDAssociate ProfessorADAM SGARDENADAM S GARDEN8442GARDEN, ADAM SProfessorSANJAYSHETESANJAY SHETE8880SHETE, SANJAYProfessorJACKPHANJACK PHAN9436PHAN, JACKAssistant Professor74Professor10Assistant Professor14Associate Professor1400 Holcombe BlvdHouston77030-4008TX1.173510.012818116research areas1.227870.041160397coauthor of96.93517.5189260similar to1142selected publicationsAuthorship 842651Authorship 843589Authorship 854918Authorship 866151Current UrologyPulmonary embolism following outpatient vasectomy. Current Urology. 9:51-53.Pulmonary embolism following outpatient vasectomyPLoS OneTreatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. PLoS One. 11.Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancerOchsner JournalDifficult conversations. Ochsner Journal. 14:712-717.Difficult conversationsOchsner JournalPemetrexed and communicating hydrocephalus. Ochsner Journal. 14:292-294.Pemetrexed and communicating hydrocephalusD002289Disorders64653060.283287Carcinoma, Non-Small-Cell LungD013727Procedures1424450.679798Terminal CareD010817Activities & Behaviors2847570.641604Physician-Patient RelationsD010166Procedures48520330.431907Palliative CareD009959Disorders16411170.517341Oropharyngeal NeoplasmsAuthorship 9140841Authorship 9151368Authorship 91664010Authorship 931889128680956Mott FEOncology and therapyPatient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. Oncol Ther. 2017; 5(1):69-74.Oncol Ther2017-01-05T00:00:002017Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions.29685701Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DRClinical lung cancerCost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer. 2018 07; 19(4):e517-e528.Clin Lung Cancer2018-03-17T00:00:002018Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy.29960060Ng SP, Johnson JM, Gunn GB, Rosenthal DI, Skinner HD, Phan J, Frank SJ, Morrison W, Sturgis EM, Mott FE, Williams MD, Fuller CD, Garden ASInternational journal of radiation oncology, biology, physicsSignificance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.Int J Radiat Oncol Biol Phys2018-06-28T00:00:002018Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer.29884417Mott FE, Ferrarotto R, Nguyen T, Phan JOral oncologyNasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncol. 2018 06; 81:75-80.Oral Oncol2018-06-01T00:00:002018Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy.Authorship 9436931Authorship 944256123046864Mott FE, Marcus JDPalliative & supportive careThe final goodbye. Palliat Support Care. 2013 Jun; 11(3):277-9.Palliat Support Care2012-10-10T00:00:002012The final goodbye.30016909Mott FE, Adams KCJournal of palliative careAdvance Care Planning and End-of-Life Issues in Head and Neck Cancer. J Palliat Care. 2019 Jan; 34(1):18-20.J Palliat Care2018-07-18T00:00:002018Advance Care Planning and End-of-Life Issues in Head and Neck Cancer.Authorship 946651231074845Pelster MS, Mott F, Lewin JThe LaryngoscopePembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer. Laryngoscope. 2020 04; 130(4):E140-E143.Laryngoscope2019-05-10T00:00:002019Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.Authorship 9611725Authorship 9612732Authorship 961492418650171Bansal M, Boyle T, Ehsan A, Mott FEClinical lung cancerBrain metastases in N2-positive non-small-cell lung cancer: implications for prophylactic cranial irradiation. Clin Lung Cancer. 2008 Jul; 9(4):227-9.Clin Lung Cancer2008-07-01T00:00:002008Brain metastases in N2-positive non-small-cell lung cancer: implications for prophylactic cranial irradiation.27300551Zhao J, Xia Y, Kaminski J, Hao Z, Mott F, Campbell J, Sadek R, Kong FMPloS oneTreatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS One. 2016; 11(6):e0157455.PLoS One2016-06-14T00:00:002016Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies.31741764El-Osta HE, Mott FE, Burt BM, Wang DY, Sabichi ALOncoimmunologyPredictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. Oncoimmunology. 2019; 8(12):e1665974.Oncoimmunology2019-09-20T00:00:002019Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis.Authorship 9787831Authorship 9794681314667273Mott FE, Cable CT, Sharma NClinical lung cancerPhase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer. 2003 Nov; 5(3):174-6.Clin Lung Cancer2003-11-01T00:00:002003Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.32193228Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JVClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.Clin Cancer Res2020-03-19T00:00:002020A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.Authorship 9892212132389639Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang JJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerProgrammed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.J Thorac Oncol2020-05-08T00:00:002020Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.Authorship 996812832779007Cardoso RC, Kamal M, Zaveri J, Chambers MS, Gunn GB, Fuller CD, Lai SY, Mott FE, McMillan H, Hutcheson KASupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerSelf-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center. Support Care Cancer. 2021 Apr; 29(4):1825-1835.Support Care Cancer2020-08-11T00:00:002020Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center.Authorship 997416132814600Mott FE, Bruera E, Johnson FPalliative & supportive careEnd-of-life and goals of care discussions with cancer patients in the coronavirus pandemic. Palliat Support Care. 2021 06; 19(3):384-385.Palliat Support Care2021-06-01T00:00:002021End-of-life and goals of care discussions with cancer patients in the coronavirus pandemic.Authorship 10077829Authorship 1007814133360375Christopherson KM, Moreno AC, Elgohari B, Gross N, Ferrarotto R, Mohamed ASR, Brandon Gunn G, Goepfert RP, Mott FE, Shah SJ, David Fuller C, Reddy JP, Frank SJ, Morrison WH, Phan J, Rosenthal DI, Garden ASOral oncologyOutcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125.Oral Oncol2020-12-22T00:00:002020Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.33364400Mott FE, Sacks R, Johnson F, Hutcheson KA, Gallagher N, Varghese S, Zaveri JLaryngoscope investigative otolaryngologySubjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI). Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1104-1109.Laryngoscope Investig Otolaryngol2020-11-06T00:00:002020Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI).Authorship 1010373733522021Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross NDHead & neckCytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.Head Neck2021-02-01T00:00:002021Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.Authorship 10118292033603241Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi BNature medicineNeoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.Nat Med2021-02-18T00:00:002021Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.Authorship 10166361333873251Guo TW, Saiyed F, Yao CMKL, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JNCancerOutcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925.Cancer2021-04-19T00:00:002021Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation.Authorship 1017800433956062Aggarwal P, Hutcheson KA, Garden AS, Mott FE, Goepfert RP, Duvall A, Fuller CD, Lai SY, Gunn GB, Sturgis EM, Hanna EY, Shete SJAMA otolaryngology-- head & neck surgeryAssociation of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2021 07 01; 147(7):615-623.JAMA Otolaryngol Head Neck Surg2021-07-01T00:00:002021Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer.Authorship 10241701434187851Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross NDClinical cancer research : an official journal of the American Association for Cancer ResearchPilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.Clin Cancer Res2021-06-29T00:00:002021Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.Authorship 1026885434358341Aggarwal P, Hutcheson KA, Garden AS, Mott FE, Lu C, Goepfert RP, Fuller CD, Lai SY, Gunn GB, Chambers MS, Sturgis EM, Hanna EY, Shete SCancerDeterminants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer. 2021 12 01; 127(23):4470-4480.Cancer2021-08-06T00:00:002021Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.Authorship 10301791134550757Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JVJournal of clinical oncology : official journal of the American Society of Clinical OncologyPoziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.J Clin Oncol2021-09-22T00:00:002021Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.Authorship 1031276634626024Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AMHead & neckPhase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.Head Neck2021-10-09T00:00:002021Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.Authorship 1033325334820641Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le XJTO clinical and research reportsEfficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep. 2021 Nov; 2(11):100237.JTO Clin Res Rep2021-10-09T00:00:002021Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations.Authorship 10390196Authorship 10411341535216923Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FEClinical lung cancerClinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 05; 23(3):236-243.Clin Lung Cancer2022-01-31T00:00:002022Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.35084077Aggarwal P, Hutcheson KA, Goepfert RP, Garden AS, Garg N, Mott FE, Fuller CD, Lai SY, Gunn GB, Chambers MS, Hanna EY, Sturgis EM, Shete SHead & neckRisk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. Head Neck. 2022 04; 44(4):952-963.Head Neck2022-01-27T00:00:002022Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors.Authorship 104390114Authorship 1044398935419587Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross NDClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.Clin Cancer Res2022-04-14T00:00:002022Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.35459784Aggarwal P, Hutcheson KA, Yu R, Wang J, Fuller CD, Garden AS, Goepfert RP, Rigert J, Mott FE, Lu C, Lai SY, Gunn GB, Chambers MS, Li G, Wu CC, Hanna EY, Sturgis EM, Shete SScientific reportsGenetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662.Sci Rep2022-04-22T00:00:002022Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors.Authorship 1047973735695117Aggarwal P, Nader ME, Gidley PW, Pratihar R, Jivani S, Garden AS, Mott FE, Goepfert RP, Ogboe CW, Charles C, Fuller CD, Lai SY, Gunn GB, Sturgis EM, Hanna EY, Hutcheson KA, Shete SCancer medicineAssociation of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. Cancer Med. 2023 01; 12(1):569-583.Cancer Med2022-06-13T00:00:002022Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors.Authorship 1065311436898078Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar AJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.J Clin Oncol2023-03-10T00:00:002023Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.Authorship 1070320737129197Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing ACancerSafety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693.Cancer2023-05-02T00:00:002023Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.Authorship 10728523Authorship 1073771237216156Singhi EK, Mott F, Worst M, Leung CH, Lee JJ, Carter B, Presley CJ, Heymach JV, Altan MOncology lettersClinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. Oncol Lett. 2023 Jun; 25(6):262.Oncol Lett2023-05-03T00:00:002023Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer.37214206Soto F, Torre-Sada LF, Mott FE, Kim ST, Nurieva R, Shannon VR, Faiz SA, Casal RF, Altan M, Lin J, Sheshadri AJournal of immunotherapy and precision oncologySarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. J Immunother Precis Oncol. 2023 May; 6(2):111-116.J Immunother Precis Oncol2023-03-21T00:00:002023Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.Authorship 10864842Authorship 1086788314579808Marcus J, Elkins G, Mott FAdvances in mind-body medicineA model of hypnotic intervention for palliative care. Adv Mind Body Med. 2003; 19(2):24-7.Adv Mind Body Med2003-01-01T00:00:002003A model of hypnotic intervention for palliative care.38197040Yennurajalingam S, Mott F, Lu Z, Urbauer D, Stanton P, Torres H, Rantanen PA, Davis S, Dev R, Hui D, Bruera EAsia-Pacific journal of oncology nursingPerception of subjective lived experiences of individuals with anorexia-cachexia in patients with advanced lung cancer. Asia Pac J Oncol Nurs. 2023 Nov; 10(Suppl 1):100314.Asia Pac J Oncol Nurs2023-10-10T00:00:002023Perception of subjective lived experiences of individuals with anorexia-cachexia in patients with advanced lung cancer.Authorship 10881741338297981Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MMThe oncologistFirst-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Jan 31.Oncologist2024-01-31T00:00:002024First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor